IRIS
BOCCARDO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 39.129
AS - Asia 16
SA - Sud America 8
NA - Nord America 3
AF - Africa 1
Totale 39.157
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 39.129
BR - Brasile 8
CN - Cina 6
SG - Singapore 5
VN - Vietnam 4
US - Stati Uniti d'America 2
BD - Bangladesh 1
BW - Botswana 1
DO - Repubblica Dominicana 1
Totale 39.157
Salva come PNG Salva come JPEG
Città #
Genova 25.260
Genoa 8.185
Rapallo 3.374
Vado Ligure 2.245
Bordighera 65
Singapore 5
Ho Chi Minh City 4
Ashburn 2
Beijing 2
Botucatu 1
Caruaru 1
Gaborone 1
Gravataí 1
Mogi Guaçu 1
Porto Alegre 1
Recife 1
Santo Domingo Este 1
São Paulo 1
Vazante 1
Totale 39.152
Salva come PNG Salva come JPEG
Nome #
Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome 222
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years 200
A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer 196
Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. 187
Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials 186
A Case of Advanced Mucinous Adenocarcinoma of Bladder in an Adult Patient Treated With Capecitabine-Based Chemotherapy and Review of Literature 183
Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer 178
Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer 174
A Case of Plasmacytoid Variant of Bladder Cancer with a Single Penile Metastasis and a Complete Response to Carboplatin-Based Chemotherapy and Review of the Literature 172
Efficacy of motesanib diphosphate in non-small-cell lung cancer. 169
Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. 169
Apalutamide treatment and metastasis-free survival in prostate cancer 167
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 166
Androgen-deprivation therapy is more than palliation in oligometastatic prostate cancer 166
A hnRNP K–AR-related signature reflects progression toward castration-resistant prostate cancer 164
Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy. 163
Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy 162
CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials 161
Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines. 160
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma 160
Prognostic variables in localized small cell neuroendocrine carcinoma of the bladder: A population-based study 160
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. 158
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials 157
Next Generation Sequencing In Non-Small Cell Lung Cancer: New Avenues Toward The Personalized Medicine. 156
Management of young women with early breast cancer 156
Differential expression of nuclear lamins in normal and cancerous prostate tissues 155
Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: A mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes 154
Adjuvant chemotherapy of bladder cancer. 153
Very late recurrence of renal cell carcinoma experiencing long-term response to sunitinib: a case report 153
Prognostic value of preoperative serum levels of periostin (PN) in early breast cancer (BCa) 152
Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma 151
Effects of three cytokine regimens on hematologic recovery and progenitor cell mobilization after high-dose cyclophosphamide, etoposide, and cisplatin. 150
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy 150
Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer 150
Intracystic epidermal growth factor level is predictive of breast-cancer risk in women with gross cystic disease of the breast 148
Cisplatin (C)-paclitaxel (P) chemotherapy (CT) regimen with concurrent radiotherapy (RT) in local advanced (LACC) or recurrent (LRCC) cervical cancer: 14 year-results of a phase II study 146
Ovarian ablation in early breast cancer: overview of the randomised trials. 145
Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study 145
Matrix-assisted laser desorption/ionisation (MALDI) TOF analysis identifies serum angiotensin II concentrations as a strong predictor of all-cause and breast cancer (BCa)-specific mortality following breast surgery 145
Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial. 144
Adjuvant therapy for patients with node negative breast cancer. 143
Paclitaxel plus organoplatins: still the gold standard in advanced ovarian cancer? 143
Alternating chemo-radiotherapy in bladder cancer: a conservative approach. 142
Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer 142
Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. 142
Combinations of hormonal therapy and chemotherapy 142
Belagenpumatucel-L for the treatment of non-small cell lung cancer 142
Targeting androgen-independent pathways: new chances for patients with prostate cancer? 142
Priming action on progesterone receptor synthesis by estradiol and tamoxifen in the 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinoma. 141
Leiomyosarcoma of the broad ligament: a case report and review of literature. 141
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. 141
Combination of sorafenib and weekly gemcitabine in patients (pts) with metastatic renal cell Cancer (MRCC): A phase II study, preliminary results 141
Switching to aromatase inhibitors in early breast cancer. 141
Urethral stricture and scrotal abscess: a rare case presentation of penile cancer and review of the literature 140
Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial 140
Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. 139
D-TRP-6-LH-RH treatment of advanced prostatic cancer 139
Bone metastases from prostate cancer: hormonal therapy 138
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. 137
Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study. 136
Periostin: A Novel Prognostic and Therapeutic Target For Genitourinary Cancer? 136
Communicating cancer diagnosis and prognosis: when the target is the elderly patient-a GIOGer study. 136
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. 136
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials 136
Long-term endocrine effects of administration of either a non-steroidal antiandrogen or a luteinizing hormone-releasing hormone agonist in men with prostate cancer. 135
Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III-IV endometrial cancer patients. 135
May adjuvant therapy play a role for the management of renal cell carcinoma? A review of literature and ongoing trials 135
Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question! 135
Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death 134
Prognostic factors in patients receiving third-line targeted therapy for metastatic renal cell carcinoma. 134
Estramustine phosphate (estracyt) following androgens in men with refractory stage D2 prostate cancer. 134
The prognostic role of baseline metabolic tumor burden and systemic inflammation biomarkers in metastatic castration-resistant prostate cancer patients treated with Radium-223: A proof of concept study 134
Re: j. Alfred witjes. A case of abiraterone acetate withdrawal. Eur urol 2013;64:517-8. 133
68P * Prognostic value of periostin (PN) expression in early breast cancer (BCa): Long-term mortality outcomes 133
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: Meta-analysis of individual patient data from ten randomised trials 133
Genitourinary tumours in the targeted therapies era: New advances in clinical practice and future perspectives 133
R75251 in prostate cancer patients in progression after first-line hormonal treatment. 132
Long-acting (depot) D-TRP-6 LH-RH (Decapeptyl) in prostate cancer. An Italian multicentric trial. 132
Incidental advanced-stage Hodgkin lymphoma diagnosed at the time of radical prostatectomy for prostatic cancer: a case report and review of literature. 132
Immunotherapy for genitourinary cancer: State of the art and new perspectives 132
Carboplatin in advanced hormone refractory prostatic cancer patients. 131
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Long term results of the Italian Tamoxifen Anastrozole trial. 131
Oral vinorelbine in the treatment of non-small-cell lung cancer. 131
Nuclear medicine and the revolution in the modern management of castration-resistant prostate cancer patients: from 223Ra-dichloride to new horizons for therapeutic response assessment 131
Prognostic value of nuclear matrix protein expression in localized prostate cancer. 131
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials 131
Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis 131
Presence and distribution of growth factors in breast cyst fluid. 130
Serum enterolactone levels and the risk of breast cancer in women with palpable cysts. 130
Use of metronomic chemotherapy in oncology: results from a national Italian survey. 130
Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era 130
Influence of bicalutamide with or without tamoxifen or anastrozole on insulin-like growth factor 1 and binding proteins in prostate cancer patients. 130
Italian national consensus conference on prostate cancer screening (Florence, May 17, 2003)--final consensus document. 130
Somatuline and tamoxifen in postmenopausal breast cancer patients. 129
Ifosfamide in urologic cancer. 129
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. 129
Chemotherapy with cisplatin and 5-fluorouracil chronomodulated infusion in locally advanced or metastatic/recurrent carcinoma of the cervix. 129
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials 129
Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients 129
Nafarelin acetate and benign prostatic hyperplasia. 128
Totale 14.624
Salva come PNG Salva come JPEG
Categoria #
all - tutte 124.557
article - articoli 112.038
book - libri 581
conference - conferenze 240
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 11.698
Totale 249.114
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.140 0 0 0 287 156 382 102 215 233 284 217 264
2021/20224.214 105 289 202 604 152 290 132 1.154 233 379 96 578
2022/20234.052 409 225 46 383 741 831 7 272 729 30 317 62
2023/20241.832 85 294 46 205 154 317 99 113 84 61 94 280
2024/20255.476 130 458 218 402 719 539 482 884 223 262 470 689
2025/20262.568 1.031 311 661 565 0 0 0 0 0 0 0 0
Totale 39.867